Finafloxacin structure
|
Common Name | Finafloxacin | ||
---|---|---|---|---|
CAS Number | 209342-40-5 | Molecular Weight | 398.388 | |
Density | 1.6±0.1 g/cm3 | Boiling Point | 686.2±55.0 °C at 760 mmHg | |
Molecular Formula | C20H19FN4O4 | Melting Point | N/A | |
MSDS | N/A | Flash Point | 368.8±31.5 °C |
Use of FinafloxacinFinafloxacin is a fluoroquinolone antimicrobial agent that exhibits optimum efficacy in slightly acidic environments. Target: AntibacterialFinafloxacin is a pH-activated fluoroquinolone (belonging to a new 8-cyano subclass) to treat serious bacterial infections associated with an acidic environment, including urinary tract infections (UTIs) and Helicobacter pylori infections. Finafloxacin exhibits optimal efficacy in slightly acidic environments (pH 5.0-6.0), under which other fluoroquinolones lose activity. Finafloxacin is highly selective for bacterial type II topoisomerases, including DNA gyrase and DNA topoisomerase IV. [1] |
Name | finafloxacin |
---|---|
Synonym | More Synonyms |
Description | Finafloxacin is a fluoroquinolone antimicrobial agent that exhibits optimum efficacy in slightly acidic environments. Target: AntibacterialFinafloxacin is a pH-activated fluoroquinolone (belonging to a new 8-cyano subclass) to treat serious bacterial infections associated with an acidic environment, including urinary tract infections (UTIs) and Helicobacter pylori infections. Finafloxacin exhibits optimal efficacy in slightly acidic environments (pH 5.0-6.0), under which other fluoroquinolones lose activity. Finafloxacin is highly selective for bacterial type II topoisomerases, including DNA gyrase and DNA topoisomerase IV. [1] |
---|---|
Related Catalog | |
References |
[1]. McKeage K. Finafloxacin: first global approval. Drugs. 2015 Apr;75(6):687-93. |
Density | 1.6±0.1 g/cm3 |
---|---|
Boiling Point | 686.2±55.0 °C at 760 mmHg |
Molecular Formula | C20H19FN4O4 |
Molecular Weight | 398.388 |
Flash Point | 368.8±31.5 °C |
Exact Mass | 398.139038 |
PSA | 107.59000 |
LogP | -0.85 |
Vapour Pressure | 0.0±2.2 mmHg at 25°C |
Index of Refraction | 1.700 |
Storage condition | 2-8℃ |
Finafloxacin |
(-)-8-Cyano-1-cyclopropyl-6-fluoro-7-((4aS,7aS)-hexahydropyrrolo(3,4-b)-1,4-oxazin-6(2H)-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid |
8-cyano-1-cyclopropyl-6-fluoro-7-((1S,6S)-2-oxa-5,8-diazabicyclo[4.3.0]non-8-yl)-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid |
QCR-30 |
3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-7-[(4aS,7aS)-hexahydropyrrolo[3,4-b]-1,4-oxazin-6(2H)-yl]-1,4-dihydro-4-oxo- |
UNII-D26OSN9Q4R |
8-cyano-1-cyclopropyl-6-fluoro-7-[(4aS,7aS)-hexahydropyrrolo[3,4-b]-1,4-oxazin-6(2H)-yl]-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid |
Finafloxacin [INN] |
7-[(4aS,7aS)-3,4,4a,5,7,7a-hexahydro-2H-pyrrolo[3,4-b][1,4]oxazin-6-yl]-8-cyano-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic acid |
Xtoro |
8-Cyano-1-cyclopropyl-6-fluoro-7-[(4aS,7aS)-hexahydropyrrolo[3,4-b][1,4]oxazin-6(2H)-yl]-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid |